drugset / Trial / NCT06540729
RC48 in Combination With AK104 and Bevacizumab in OCCC
NaSingle-groupOpen-labelTreatment
Summary
Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Timeline
- Start
- 2024-09-24
- Primary completion
- 2028-08-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | — |